The results regarding progression-free survival (PFS) showed that a high expression of FDX1 was significantly associated with low risk in KIRC (HR = 0.444), MESO (HR = 0.425), and THCA (HR = 0.205) but with higher risk in ACC (HR = 1.277) and LGG (HR = 2.883) (all p < 0.05). Here, FDX1 is linked to adrenal cortex carcinoma.